Show simple item record

dc.contributor.authorAntoun Reyad, Ayman
dc.contributor.authorPlaha, Kiran
dc.contributor.authorGirgis, Eriny
dc.contributor.authorMishriky, Raafat
dc.date.accessioned2020-04-07T13:40:36Z
dc.date.available2020-04-07T13:40:36Z
dc.date.issued2020-06-04
dc.identifier.citationAntoun Reyad, A., Plaha, K., Girgis, E. and Mishriky, R. (2020) Fluoxetine in the management of major depressive disorder in children and adolescents: A meta-analysis of randomized controlled trials, Hospital Pharmacy DOI: 10.1177/0018578720925384en
dc.identifier.issn0018-5787en
dc.identifier.doi10.1177/0018578720925384
dc.identifier.urihttp://hdl.handle.net/2436/623174
dc.descriptionThis is an accepted manuscript of an article to be published by SAGE in Hospital Pharmacy on 04/06/2020. The accepted version of the publication may differ from the final published version.en
dc.description.abstractFluoxetine is a serotonin specific reuptake inhibitor anti-depressant and is the only approved pharmacological treatment for major depressive disorder (MDD) in children and adolescent. We searched the published randomized controlled-trials (RCT) to review fluoxetine efficacy and tolerability using the databases PubMed, EUDRACT, ClinicalTrials.gov and Cochrane Central Register of Controlled Trials for fluoxetine role in managing MDD in children and adolescents. A meta-analysis was conducted using the identified 7 clinical trials to assess efficacy using the outcomes: Children’s Depression Rating Scale-Revised (CDRS-R), Clinical Global Impressions – Severity of Illness (CGI-S) and Clinical Global Impressions – Improvement (CGI-I) response rate. The risk of discontinuation due to adverse effects and common side effects were examined. The mean difference in change from baseline for CDRS-R was -2.72 [95% Confidence Interval (CI) -3.96, -1.48] favouring fluoxetine treatment (p<0.001). Similarly, mean difference for CGI-S was -0.21 [95% CI -0.36, -0.06]. The risk ratio (RR) of discontinuing due to adverse events was 0.98 [95% CI 0.54, 1.83], with RR for headache side effects 1.34 [95% CI 1.03, 1.74] and rash 2.6 [95% CI 1.32, 5.14]. Fluoxetine demonstrates significant improvements in symptom intensity control in young patients suffering from MDD and is considered well-tolerated with similar rates of trials discontinuation; however, fluoxetine was associated with a higher risk of headache and rash side effects. These findings will guide psychiatrists and pharmacists in their clinical role for supporting the care of young mental health patients.en
dc.formatapplication/pdfen
dc.language.isoenen
dc.publisherThomas Land Publishers Inc.en
dc.relation.urlhttps://journals.sagepub.com/doi/10.1177/0018578720925384en
dc.subjectFluoxetineen
dc.subjectMajor Depressive Disordersen
dc.titleFluoxetine in the management of major depressive disorder in children and adolescents: A meta-analysis of randomized controlled trialsen
dc.typeJournal articleen
dc.identifier.journalHospital Pharmacyen
dc.date.updated2020-04-05T16:12:00Z
dc.date.accepted2020-04-01
rioxxterms.funderUniversity of Wolverhamptonen
rioxxterms.identifier.projectUOW07042020AARen
rioxxterms.versionAMen
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/en
rioxxterms.licenseref.startdate2020-04-07en
refterms.dateFCD2020-04-07T13:21:33Z
refterms.versionFCDAM
refterms.dateFOA2020-04-07T13:40:37Z


Files in this item

Thumbnail
Name:
Antoun_Reyad_Fluoxetine_ 2020.pdf
Size:
828.2Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc-nd/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/